Synovus Financial’s Big Healthcare Share Position in Q3 Fund Filing: JNJ, UNH, ABT, PFE, BMY, MRK

Wall St. Watchdog reveals information regarding Synovus Financial’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 59 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $96.747 million.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, Synovus Financial reported holding 293,817 shares with a market value of $19,544,706. This comprised 0.69% of the total portfolio. On 09/30/2011, Synovus Financial reported holding 291,827 shares with a market value of $18,586,461. This comprised 0.75% of the total portfolio. The net change in shares for this position over the two quarters is -1,990. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, Synovus Financial reported holding 183,092 shares with a market value of $9,443,886. This comprised 0.33% of the total portfolio. On 09/30/2011, Synovus Financial reported holding 229,028 shares with a market value of $10,562,771. This comprised 0.42% of the total portfolio. The net change in shares for this position over the two quarters is 45,936. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, Synovus Financial reported holding 187,732 shares with a market value of $9,878,458. This comprised 0.35% of the total portfolio. On 09/30/2011, Synovus Financial reported holding 204,566 shares with a market value of $10,461,505. This comprised 0.42% of the total portfolio. The net change in shares for this position over the two quarters is 16,834. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, Synovus Financial reported holding 438,962 shares with a market value of $9,042,617. This comprised 0.32% of the total portfolio. On 09/30/2011, Synovus Financial reported holding 488,843 shares with a market value of $8,642,744. This comprised 0.35% of the total portfolio. The net change in shares for this position over the two quarters is 49,881. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Intuitive Surgical Inc. (NASDAQ:ISRG): On 06/30/2011, Synovus Financial reported holding 19,782 shares with a market value of $7,361,080. This comprised 0.26% of the total portfolio. On 09/30/2011, Synovus Financial reported holding 19,482 shares with a market value of $7,096,903. This comprised 0.28% of the total portfolio. The net change in shares for this position over the two quarters is -300. About Company: Intuitive Surgical, Inc. design, manufactures and markets surgical systems. The Company’s surgical system controls Intuitive Surgical endoscopic instruments, including rigid endoscopes, blunt and sharp endoscopic dissectors, scissors, scalpels, forceps/pickups, needle holders, endoscopic retractors, electrocautery, ultrasonic cutters, and accessories during surgical procedures.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, Synovus Financial reported holding 203,756 shares with a market value of $7,190,549. This comprised 0.25% of the total portfolio. On 09/30/2011, Synovus Financial reported holding 208,873 shares with a market value of $6,830,147. This comprised 0.27% of the total portfolio. The net change in shares for this position over the two quarters is 5,117. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, Synovus Financial reported holding 184,810 shares with a market value of $5,352,097. This comprised 0.19% of the total portfolio. On 09/30/2011, Synovus Financial reported holding 181,444 shares with a market value of $5,693,713. This comprised 0.23% of the total portfolio. The net change in shares for this position over the two quarters is -3,366. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Gilead Sciences Inc. (NASDAQ:GILD): On 06/30/2011, Synovus Financial reported holding 139,661 shares with a market value of $5,783,362. This comprised 0.2% of the total portfolio. On 09/30/2011, Synovus Financial reported holding 138,195 shares with a market value of $5,361,966. This comprised 0.22% of the total portfolio. The net change in shares for this position over the two quarters is -1,466. About Company: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company’s primary arees of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
  • Perrigo Co. (NASDAQ:PRGO): On 06/30/2011, Synovus Financial reported holding 72,119 shares with a market value of $6,337,097. This comprised 0.22% of the total portfolio. On 09/30/2011, Synovus Financial reported holding 46,039 shares with a market value of $4,470,847. This comprised 0.18% of the total portfolio. The net change in shares for this position over the two quarters is -26,080. About Company: Perrigo Company manufactures store brand over-the-counter pharmaceutical products and also manufactures store brand nutritional products. The Company’s customers include major national and regional retail drug, supermarket, and mass merchandise chains such as Albertson’s, CVS, and Target, and major wholesalers such as Super Valu and McKesson.
  • Hologic Inc. (NASDAQ:HOLX): On 06/30/2011, Synovus Financial reported holding 242,308 shares with a market value of $4,887,352. This comprised 0.17% of the total portfolio. On 09/30/2011, Synovus Financial reported holding 235,008 shares with a market value of $3,574,472. This comprised 0.14% of the total portfolio. The net change in shares for this position over the two quarters is -7,300. About Company: Hologic, Inc. develops, manufactures, and markets x-ray systems. The Company makes x-ray bone densitometers that measure the precise bone density for use in the diagnosing of metabolic bone diseases such as osteoporosis.

(Note: Data regarding Synovus Financial’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>